|1.||Weller, M: 16 articles (04/2008 - 01/2000)|
|2.||Yagita, Hideo: 14 articles (06/2014 - 02/2002)|
|3.||Krammer, P H: 9 articles (09/2015 - 10/2000)|
|4.||Kuo, Po-Lin: 9 articles (05/2014 - 09/2004)|
|5.||Fukunaga, Kohji: 9 articles (01/2012 - 08/2002)|
|6.||Zou, Ping: 9 articles (10/2006 - 01/2002)|
|7.||Krammer, Peter H: 8 articles (11/2015 - 02/2003)|
|8.||Peter, Marcus E: 8 articles (04/2014 - 08/2004)|
|9.||Legembre, Patrick: 8 articles (11/2013 - 08/2004)|
|10.||Hsu, Ya-Ling: 8 articles (10/2011 - 09/2004)|
12/01/2012 - "The composition of cancerous exosomes has been proven to play pivotal roles in the maintenance of the microenvironment that is beneficial for the progression of cancer, such as Fas-ligand-triggered lymphocyte apoptosis. "
12/01/2012 - "Fas ligand (FasL) gene therapy for cancer has shown promise in rodents; however, its efficacy in higher mammals remains unknown. "
06/01/2014 - "Several studies have assessed the association of CD95L polymorphism with cervical cancer risk, but the data lack the power to provide compelling evidence. "
05/01/2014 - "Genetic polymorphisms in the Fas/Fas ligand (FasL) gene were proposed to be associated with susceptibility to cervical cancer, but previous studies reported controversial findings. "
01/01/2013 - "Published studies investigating the association between genetic polymorphism -884C/T (rs763110) of the FAS ligand (FASL) promoter and cancer risk reported inconclusive results. "
|2.||Neoplasm Metastasis (Metastasis)
12/01/2011 - "Low preoperatives CD95L levels may help identify a subgroup of patients with synchronous liver metastases that are likely to benefit from liver surgery."
12/01/2011 - "Preoperatives CD95L is a potential prognostic factor for RFS and OS of patients undergoing surgery for synchronous colorectal liver metastases. "
12/01/2011 - "To assess whether circulating soluble CD95 ligand (sCD95L) levels are associated with recurrence-free survival (RFS) in patients with synchronous colorectal liver metastases. "
12/01/2010 - "Micro-metastases in the hypoxic transition zone following RFA displayed a highly invasive phenotype and increased expression of CD95 and CD95L. "
01/01/2007 - "Moreover, negative staining for Fas or the lack of Fas-ligand expression proved to be significant predictors for the survival free from bone metastases under univariate analysis. "
05/15/1999 - "This study also indicates that the failing heart may contribute to the increased concentration of soluble Fas ligand in patients with congestive heart failure."
01/01/2012 - "The Fas/Fas Ligand system is a major apoptosis signaling pathway that is up-regulated in patients with chronic heart failure (CHF). "
06/01/2006 - "We postulate that the Fas ligand (FasL) derived from the infiltrating mononuclear cells causes death of cardiac cells resulting in the development of heart failure. "
09/17/2004 - "Blockade of this apoptosis by interfering with the Fas/Fas ligand interaction may become one of the therapeutic strategies against chronic heart failure after large MI."
05/15/1999 - "The circulating levels of soluble Fas ligand was increased in patients with advanced congestive heart failure. "
|4.||Melanoma (Melanoma, Malignant)
08/01/2010 - "Overexpression of the death ligand CD95L/FasL has been shown in previous studies as highly effective for apoptosis induction in melanoma cells. "
07/01/2010 - "FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study."
08/01/1998 - "The present study indicates the significant correlation between tumorigenicity and expression of CD95L, and thereby raises the possibility that CD95L may be a useful diagnostic marker for malignant melanomas."
08/01/1998 - "In this study, we employed immunohistochemistry using an antibody directed against CD95L to investigate at which stage the melanoma CD95L expression is turned on. "
03/01/2007 - "To this end we used a Fas ligand (FasL)-expressing melanoma cell line in a mouse model. "
08/01/2001 - "In contrast, mice with defects in the Fas/Fas ligand (FasL)-mediated cytotoxicity pathway exhibit delayed clearance of adenovirus from the liver without apparent delay in the clearance of viral infections from extrahepatic organs. "
04/15/2010 - "Previous studies have shown that the reduction in CD8 T cell immunity observed during high-dose influenza A virus (IAV) infection is mediated via lymph node (LN) dendritic cells (DCs) that express Fas ligand (FasL) and drive FasL-Fas (DC-T)-induced apoptosis. "
11/01/2009 - "In this study, we examined the roles of Fas-Fas ligand (FasL) signaling in lethal infection with HSV-2 by using mice with mutated Fas (lpr) or FasL (gld) in C57BL/6 background. "
11/01/2007 - "In this study, we evaluated the contribution of Fas-Fas ligand (FasL) interactions to CD8+ T-cell-mediated control of WNV infection. "
08/01/2006 - "The aim of this study was to analyze the expression levels of TGFbeta1, soluble form of CD95, CD95 ligand (sCD95 and sCD95L, respectively) in plasma and CD95 expression on CD3(+) cells, CD38 expression on CD8(+) cells in liver transplanted recipients with active HCMV infection. "
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Fas Ligand Protein (Fas Ligand)
|5.||Interleukin-10 (Interleukin 10)
|7.||Interleukin-6 (Interleukin 6)
|8.||Interferon-gamma (Interferon, gamma)
|9.||Messenger RNA (mRNA)
|10.||Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
|1.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)